Abstract
In recent years, genes associated with cancer have been studied to assess their possible use as predictive indicators for cancer therapies. Among these, the gene product of the tumor suppressor gene p53 was found to play an important role in cancer therapy. The p53 molecule induces cell-cycle arrest, apoptosis and DNA repair after cells are subjected to cancer therapies involving radiation, heat and various anti-cancer agents. Mutations in p53 are observed at a high frequency in human tumors, and are present in about half of all malignant tumors in humans. Sensitization to radiation, heat and anti-cancer agents was observed in cells containing wild type p53, but not in cells containing mutated p53. This review discusses p53 activation of signaling pathways after exposure to cancer therapies which target p53; such therapies include chemical chaperones, the p53 gene, p53-C terminal peptides, and p53-targeting agents which enhance p53-central signal transduction pathways.
Keywords: p53, chemical chaperones, apoptosis, radiation, heat
Anti-Cancer Agents in Medicinal Chemistry
Title: p53 Targeting Can Enhance Cancer Therapy via Radiation, Heat and Anti-Cancer Agents
Volume: 8 Issue: 5
Author(s): Takeo Ohnishi, Akihisa Takahashi, Eiichiro Mori and Ken Ohnishi
Affiliation:
Keywords: p53, chemical chaperones, apoptosis, radiation, heat
Abstract: In recent years, genes associated with cancer have been studied to assess their possible use as predictive indicators for cancer therapies. Among these, the gene product of the tumor suppressor gene p53 was found to play an important role in cancer therapy. The p53 molecule induces cell-cycle arrest, apoptosis and DNA repair after cells are subjected to cancer therapies involving radiation, heat and various anti-cancer agents. Mutations in p53 are observed at a high frequency in human tumors, and are present in about half of all malignant tumors in humans. Sensitization to radiation, heat and anti-cancer agents was observed in cells containing wild type p53, but not in cells containing mutated p53. This review discusses p53 activation of signaling pathways after exposure to cancer therapies which target p53; such therapies include chemical chaperones, the p53 gene, p53-C terminal peptides, and p53-targeting agents which enhance p53-central signal transduction pathways.
Export Options
About this article
Cite this article as:
Ohnishi Takeo, Takahashi Akihisa, Mori Eiichiro and Ohnishi Ken, p53 Targeting Can Enhance Cancer Therapy via Radiation, Heat and Anti-Cancer Agents, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (5) . https://dx.doi.org/10.2174/187152008784533017
DOI https://dx.doi.org/10.2174/187152008784533017 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multiple Pharmacological Properties of a Novel Parthenin Analog P16 as Evident by its Cytostatic and Antiangiogenic Potential Against Pancreatic Adenocarcinoma PANC -1 Cells
Anti-Cancer Agents in Medicinal Chemistry Enhancement of Hepatoprotective Efficacy of Propolis by Fabrication of Liposomes, as a Platform Nano-Formulation for Multi-Component Natural Medicine
Current Drug Delivery Extracellular Vesicles as Novel Delivery Tools for Cancer Treatment
Current Cancer Drug Targets Antibody Based Therapies in Acute Leukemia
Current Drug Targets Effect of Flavonoids on Human Health: Old Subjects but New Challenges
Recent Patents on Biotechnology Effects of Dietary Polyunsaturated Fatty Acids on Mitochondria
Current Pharmaceutical Design Metastasis: Recent Discoveries and Novel Perioperative Treatment Strategies with Particular Interest in the Hemostatic Compound Desmopressin
Current Pharmaceutical Biotechnology Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review
Current Cancer Drug Targets Thiol-Activated Anticancer Agents: The State of the Art
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Targets in Triple Negative Breast Cancer - Where are we now?
Recent Patents on Anti-Cancer Drug Discovery STAT3: A Potential Drug Target for Tumor and Inflammation
Current Topics in Medicinal Chemistry Integrating Bioinformatics Strategies in Cancer Immunotherapy: Current and Future Perspectives
Combinatorial Chemistry & High Throughput Screening Pleiotropic Effects of PPARγ Agonist on Hemostatic Activation in Type 2 Diabetes Mellitus
Current Vascular Pharmacology Parametric MR Dynamic Imaging for Breast Lesions Characterization and Prediction of Lymph Nodes Involvement
Current Radiopharmaceuticals Current Limitations in the Treatment of Parkinson’s and Alzheimer’s Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers
Current Medicinal Chemistry MiR-509-3-5p-NONHSAT112228.2 Axis Regulates p21 and Suppresses Proliferation and Migration of Lung Cancer Cells
Current Topics in Medicinal Chemistry Drug Design for Protein Kinases and Phosphatases: Flexible-Receptor Docking, Binding Affinity and Specificity, and Drug-Binding Kinetics
Current Pharmaceutical Design ATF4, an ER Stress and Hypoxia-Inducible Transcription Factor and its Potential Role in Hypoxia Tolerance and Tumorigenesis
Current Molecular Medicine Pharmacokinetic and Metabolism Determinants of Fluoropyrimidines and Oxaliplatin Activity in Treatment of Colorectal Patients
Current Drug Metabolism